Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc

In S. Kim, Tae M. Yoo, Hisataka Kobayashi, Meyoung-Kon Kim, Nhat Le, Q. C. Wang, Ira Pastan, Jorge A. Carrasquillo, Chang H. Paik

Research output: Contribution to journal › Article

25 Citations (Scopus)

Abstract

The anti-Tac disulfide-bonded variable region fragment (dsFv) is a genetically engineered, 25 kDa, murine monoclonal antibody fragment that recognizes the α subunit of the interleukin-2 receptor (IL-2Rα). The dsFv radiolabeled with the tetrafluorophenyl ester (TFP) of [99mTc]mercaptoacetyltriglycine ([99mTc]MAG3-TFP) showed rapid tumor uptake and fast blood clearance in mice, resulting in high tumor-to-nontumor background ratios. However, its high renal uptake was a problem. In this study, we tested the effect of lowering the isoelectric point (pI) of dsFv to <9.3 on renal and tumor uptake. To lower the pI, dsFv was acylated simultaneously with both [99mTc]MAG3-TFP and TFP-glycolate. The acylation of dsFv decreased its pI and its immunoreactivity inversely proportional to the molar ratio of TFP-glycolate to dsFv, whereas the conjugation of [99mTc]MAG3-TFP alone did not. When biodistribution studies were performed in nude mice, the effect of the lowered pI was reflected primarily in decreased kidney uptake and whole-body retention, with its highest effect seen at the earliest time point (15 min) after injection. In tumor-bearing nude mice, glycolated [99mTc]MAG3-dsFv with a pI range of 4.9 to 6.5 accumulated selectively into IL-2 receptor-positive SP2/Tac tumor similar to that of the control [125I]dsFv labeled by the Iodo-Gen method, whereas its renal uptake was 25% of [125I]dsFv at 15 min. At 90 min, the ratios of tumor to receptor-negative SP2/0 tumor, liver, kidney, stomach, and blood had peaked at 10.9, 8.5, 0.3, 5.0, and 6.2, respectively, for the glycolated [99mTc]MAG3-dsFv. The corresponding ratios for [125I]dsFv were 3.7, 5.0, 0.1, 1.5, and 2.1, respectively.

Original languageEnglish
Pages (from-to)447-453
Number of pages7
JournalBioconjugate Chemistry
Volume10
Issue number3
DOIs
Publication statusPublished - 1999 May 1
Externally publishedYes

Fingerprint

Technetium Tc 99m Mertiatide
Monoclonal antibodies
Chemical modification
Disulfides
Tumors
Monoclonal Antibodies
Esters
glycolic acid
Kidney
Neoplasms
Interleukin-2 Receptors
Nude Mice
Blood
Bearings (structural)
Acylation
Immunoglobulin Fragments
Isoelectric Point
Liver
Stomach
Injections

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. / Kim, In S.; Yoo, Tae M.; Kobayashi, Hisataka; Kim, Meyoung-Kon; Le, Nhat; Wang, Q. C.; Pastan, Ira; Carrasquillo, Jorge A.; Paik, Chang H.

In: Bioconjugate Chemistry, Vol. 10, No. 3, 01.05.1999, p. 447-453.

Research output: Contribution to journal › Article

Kim, IS, Yoo, TM, Kobayashi, H, Kim, M-K, Le, N, Wang, QC, Pastan, I, Carrasquillo, JA & Paik, CH 1999, 'Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc', Bioconjugate Chemistry, vol. 10, no. 3, pp. 447-453. https://doi.org/10.1021/bc980129m
Kim IS, Yoo TM, Kobayashi H, Kim M-K, Le N, Wang QC et al. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. Bioconjugate Chemistry. 1999 May 1;10(3):447-453. https://doi.org/10.1021/bc980129m
Kim, In S. ; Yoo, Tae M. ; Kobayashi, Hisataka ; Kim, Meyoung-Kon ; Le, Nhat ; Wang, Q. C. ; Pastan, Ira ; Carrasquillo, Jorge A. ; Paik, Chang H. / Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. In: Bioconjugate Chemistry. 1999 ; Vol. 10, No. 3. pp. 447-453.
@article{ecb5a4b8d6db4f6a816d2128c6533e5f,
title = "Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc",
abstract = "The anti-Tac disulfide-bonded variable region fragment (dsFv) is a genetically engineered, 25 kDa, murine monoclonal antibody fragment that recognizes the α subunit of the interleukin-2 receptor (IL-2Rα). The dsFv radiolabeled with the tetrafluorophenyl ester (TFP) of [99mTc]mercaptoacetyltriglycine ([99mTc]MAG3-TFP) showed rapid tumor uptake and fast blood clearance in mice, resulting in high tumor-to-nontumor background ratios. However, its high renal uptake was a problem. In this study, we tested the effect of lowering the isoelectric point (pI) of dsFv to <9.3 on renal and tumor uptake. To lower the pI, dsFv was acylated simultaneously with both [99mTc]MAG3-TFP and TFP-glycolate. The acylation of dsFv decreased its pI and its immunoreactivity inversely proportional to the molar ratio of TFP-glycolate to dsFv, whereas the conjugation of [99mTc]MAG3-TFP alone did not. When biodistribution studies were performed in nude mice, the effect of the lowered pI was reflected primarily in decreased kidney uptake and whole-body retention, with its highest effect seen at the earliest time point (15 min) after injection. In tumor-bearing nude mice, glycolated [99mTc]MAG3-dsFv with a pI range of 4.9 to 6.5 accumulated selectively into IL-2 receptor-positive SP2/Tac tumor similar to that of the control [125I]dsFv labeled by the Iodo-Gen method, whereas its renal uptake was 25{\%} of [125I]dsFv at 15 min. At 90 min, the ratios of tumor to receptor-negative SP2/0 tumor, liver, kidney, stomach, and blood had peaked at 10.9, 8.5, 0.3, 5.0, and 6.2, respectively, for the glycolated [99mTc]MAG3-dsFv. The corresponding ratios for [125I]dsFv were 3.7, 5.0, 0.1, 1.5, and 2.1, respectively.",
author = "Kim, {In S.} and Yoo, {Tae M.} and Hisataka Kobayashi and Meyoung-Kon Kim and Nhat Le and Wang, {Q. C.} and Ira Pastan and Carrasquillo, {Jorge A.} and Paik, {Chang H.}",
year = "1999",
month = "5",
day = "1",
doi = "10.1021/bc980129m",
language = "English",
volume = "10",
pages = "447--453",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc

AU - Kim, In S.

AU - Yoo, Tae M.

AU - Kobayashi, Hisataka

AU - Kim, Meyoung-Kon

AU - Le, Nhat

AU - Wang, Q. C.

AU - Pastan, Ira

AU - Carrasquillo, Jorge A.

AU - Paik, Chang H.

PY - 1999/5/1

Y1 - 1999/5/1

N2 - The anti-Tac disulfide-bonded variable region fragment (dsFv) is a genetically engineered, 25 kDa, murine monoclonal antibody fragment that recognizes the α subunit of the interleukin-2 receptor (IL-2Rα). The dsFv radiolabeled with the tetrafluorophenyl ester (TFP) of [99mTc]mercaptoacetyltriglycine ([99mTc]MAG3-TFP) showed rapid tumor uptake and fast blood clearance in mice, resulting in high tumor-to-nontumor background ratios. However, its high renal uptake was a problem. In this study, we tested the effect of lowering the isoelectric point (pI) of dsFv to <9.3 on renal and tumor uptake. To lower the pI, dsFv was acylated simultaneously with both [99mTc]MAG3-TFP and TFP-glycolate. The acylation of dsFv decreased its pI and its immunoreactivity inversely proportional to the molar ratio of TFP-glycolate to dsFv, whereas the conjugation of [99mTc]MAG3-TFP alone did not. When biodistribution studies were performed in nude mice, the effect of the lowered pI was reflected primarily in decreased kidney uptake and whole-body retention, with its highest effect seen at the earliest time point (15 min) after injection. In tumor-bearing nude mice, glycolated [99mTc]MAG3-dsFv with a pI range of 4.9 to 6.5 accumulated selectively into IL-2 receptor-positive SP2/Tac tumor similar to that of the control [125I]dsFv labeled by the Iodo-Gen method, whereas its renal uptake was 25% of [125I]dsFv at 15 min. At 90 min, the ratios of tumor to receptor-negative SP2/0 tumor, liver, kidney, stomach, and blood had peaked at 10.9, 8.5, 0.3, 5.0, and 6.2, respectively, for the glycolated [99mTc]MAG3-dsFv. The corresponding ratios for [125I]dsFv were 3.7, 5.0, 0.1, 1.5, and 2.1, respectively.

AB - The anti-Tac disulfide-bonded variable region fragment (dsFv) is a genetically engineered, 25 kDa, murine monoclonal antibody fragment that recognizes the α subunit of the interleukin-2 receptor (IL-2Rα). The dsFv radiolabeled with the tetrafluorophenyl ester (TFP) of [99mTc]mercaptoacetyltriglycine ([99mTc]MAG3-TFP) showed rapid tumor uptake and fast blood clearance in mice, resulting in high tumor-to-nontumor background ratios. However, its high renal uptake was a problem. In this study, we tested the effect of lowering the isoelectric point (pI) of dsFv to <9.3 on renal and tumor uptake. To lower the pI, dsFv was acylated simultaneously with both [99mTc]MAG3-TFP and TFP-glycolate. The acylation of dsFv decreased its pI and its immunoreactivity inversely proportional to the molar ratio of TFP-glycolate to dsFv, whereas the conjugation of [99mTc]MAG3-TFP alone did not. When biodistribution studies were performed in nude mice, the effect of the lowered pI was reflected primarily in decreased kidney uptake and whole-body retention, with its highest effect seen at the earliest time point (15 min) after injection. In tumor-bearing nude mice, glycolated [99mTc]MAG3-dsFv with a pI range of 4.9 to 6.5 accumulated selectively into IL-2 receptor-positive SP2/Tac tumor similar to that of the control [125I]dsFv labeled by the Iodo-Gen method, whereas its renal uptake was 25% of [125I]dsFv at 15 min. At 90 min, the ratios of tumor to receptor-negative SP2/0 tumor, liver, kidney, stomach, and blood had peaked at 10.9, 8.5, 0.3, 5.0, and 6.2, respectively, for the glycolated [99mTc]MAG3-dsFv. The corresponding ratios for [125I]dsFv were 3.7, 5.0, 0.1, 1.5, and 2.1, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0033137010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033137010&partnerID=8YFLogxK

U2 - 10.1021/bc980129m

DO - 10.1021/bc980129m

M3 - Article

C2 - 10346877

AN - SCOPUS:0033137010

VL - 10

SP - 447

EP - 453

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 3

ER -

Access to Document